ArticleCancer cell international2015
Cyclooxygeanse-2 promotes metastasis in osteosarcoma.
Article in Cancer cell international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis.FEBS open bio · 2019Pooled it
- Repurposing of Indomethacin and Naproxen as anticancer agents: progress from 2017 to present.RSC advances · 2024Review
- Recent Advancements in Refashioning of NSAIDs and their Derivatives as Anticancer Candidates.Current pharmaceutical design · 2024Review
- Nano-Based Drug Delivery Systems: Potential Developments in the Therapy of Metastatic Osteosarcoma-A Narrative Review.Pharmaceutics · 2023Review
- Role of TRP Channels in Liver-Related Diseases.International journal of molecular sciences · 2023Review
- Immunophenotyping of an Unusual Mixed-Type Extraskeletal Osteosarcoma in a Dog.Veterinary sciences · 2021Article
- A naturally derived small molecule PSM0537 targets the AF1Q-TCF4 interaction to suppress COX2 expression and inhibit cell proliferation and metastasis in osteosarcoma.American journal of cancer research · 2021Article
- Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma.Histology and histopathology · 2020Article
- Selective Inhibition of Liver Cancer Cells Using Venom Peptide.Marine drugs · 2019Article
- Identification of Prognostic and Predictive Osteosarcoma Biomarkers.Medical sciences (Basel, Switzerland) · 2019Review
- High Expression ofJournal of Cancer · 2019Article
- Progress in the chemotherapeutic treatment of osteosarcoma.Oncology letters · 2018Review
- Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin increases the activation of aryl hydrocarbon receptor and is associated with the aggressiveness of osteosarcoma MG-63 osteoblast-like cells.Oncology letters · 2018Article
- A support vector machine classifier for the prediction of osteosarcoma metastasis with high accuracy.International journal of molecular medicine · 2017Article
- Exploring the key genes and pathways of osteosarcoma with pulmonary metastasis using a gene expression microarray.Molecular medicine reports · 2017Article
- Regulation of Osteosarcoma Cell Proliferation, Migration, and Invasion by miR-143 and miR-199a Through COX-2 Targeting.Dose-response : a publication of International Hormesis SocietyArticle
- Palliative Care in Musculoskeletal Oncology.Indian journal of palliative careReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclooxygenase-2 (COX-2), an inducible form of the enzyme that catalyzes the first step in the synthesis of prostanoids, is associated with carcinogenesis, which is suspected to promote angiogenesis and tissue invasion of tumors and resistance to apoptosis. COX-2 is also involved in metastasis and poor prognosis of cancer. Osteosarcoma with COX-2 positivity is from 67 to 92 %. COX-2-positive rate in metastatic lesions was greater than that of biopsy and/or resected samples of the primary site in osteosarcoma. And, what role does COX-2 play in osteosarcoma metastasis? Genetic studies support a cause-effect connection between COX-2 and tumorigenesis. COX-2 expression had a poor prognosis with regard to metastasis, and patients with increased COX-2 expression in lung metastases died of the disease. COX-2 expression has also been established as a marker in human osteosarcoma, and COX-2 inhibition has been suggested as a possible way of improving therapeutic outcome. In addition, COX-inhibitors inhibit the tumor initiation, matrix metalloproteinases (MMPs), cell differentiation and T cell proliferation and suppression of the antitumor activity of natural killer cells and macrophages, angiogenic mechanism. Therefore, we can exert the COX-inhibitors to potentialize the effects of chemotherapeutic agents, and reverse the metastasis in osteosarcoma to facilitate the patient who may benefit from addition of COX-inhibitors to standard cytotoxic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.